Antibody Partnering Terms and Agreements -





 

Updated: June 2014 Edition: 5 Pages: 1449 including appendices 

The Antibody Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the antibody partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter antibody partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. 

 

This report provides details of the latest antibody agreements announced in the healthcare sectors, covering: 

 

  • Antibodies
  • Antibody-drug conjugates
  • Monoclonal antibodies
    • Murine mAb
    • Chimeric mAb
    • Humanized mAb
    • Human aAb
    • Polyclonal Antibodies
     

 

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

                                

This report contains over 900 links to online copies of actual antibody deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

 

The initial chapters of this report provide an orientation of antibody dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in antibody dealmaking since 2009, including details of average headline, upfront, milestone and royalty terms.

                    

Chapter 3 provides a review of the leading antibody deals since 2009. Deals are listed by headline value, signed by big pharma, most active big pharma and big biotech, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

 

Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of antibody deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

 

Chapter 5 provides a comprehensive listing of the top 50 big biotech companies with antibodies deals announced along with a brief summary followed by a comprehensive listing of antibody deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.

 

Chapter 6 provides a comprehensive and detailed review of antibody partnering deals signed and announced since 2009, where a contract document is available in the public domain. The chapter is organized by stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), specific therapy focus and specific technology type. Each deal title links via Weblink to an online version of the deal record and the contract document, providing easy access to each contract document on demand.

 

Chapter 7 provides a comprehensive and detailed review of antibody partnering deals signed and announced since January 2009. The chapter is organized by specific antibody technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

The report also includes numerous tables and figures that illustrate the trends and activities in antibody partnering and dealmaking since 2009.

 

In addition, a comprehensive appendix is provided organized by antibody partnering company A-Z ,deal type, stage of development type and therapy type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

                                                  

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of antibody technologies and products.

 

Report scope

                          

Antibody Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to antibody trends and structure of deals entered into by leading companies worldwide.

                                              

Antibody Partnering Terms and Agreements includes:

                                                       

  • Trends in antibody dealmaking in the biopharma industry since 2009
  • Analysis of antibody deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life antibody deals
  • Access to over 900 antibody contract documents
  • The leading antibody deals by value since 2009
  • Most active antibody dealmakers since 2009
  • The leading antibody partnering resources

  

In Antibody Partnering Terms and Agreements, the available contracts are listed by:

 

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal component type
  • Specific therapy target

 

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

 

 The Antibody Partnering Terms and Agreements report provides comprehensive access to available deals and contract documents for over 1,500 antibody deals. Analyzing actual contract agreements allows assessment of the following:

                                 

  • What are the precise antibody rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How aresalesand payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

 

Executive Summary 

Chapter 1 – Introduction 

Chapter 2 – Trends in antibody dealmaking 

2.1. Introduction

2.2. Antibody partnering over the years

2.3. Big pharma antibody dealmaking activity

2.4 Big Biotech antibody dealmaking activity

2.5. Top 10 active antibody dealmakers

2.6. Antibody partnering by deal type

2.7. Antibody partnering by disease type

2.8. Antibody partnering by stage of development

2.9. Partnering by antibody type

2.10. Average deal terms for antibody partnering

2.10.1 Antibody headline values

2.10.2 Antibody upfront payments

2.10.3 Antibody milestone payments

2.10.4 Antibody royalty rates

2.11. The anatomy of antibody partnering

2.11.a. Case study 1: ADMA Biologics- Biotest: December 31 2012

2.11.b. Case study 2: Amgen- AstraZeneca: April 2, 2012

Chapter 3 – Leading antibody deals 

3.1. Introduction

3.2. Top antibody deals by value

Chapter 4 – Big pharma antibody deals 

4.1. Introduction

4.2. How to use big pharma antibody partnering deals

4.3. Big pharma antibody partnering company profiles

Abbott

Amgen

Astellas

AstraZeneca

Baxter International

Bayer

Biogen Idec

Boehringer Ingelheim

Bristol-Myers Squibb

Celgene

CSL

Daiichi Sankyo

Eisai

Eli Lilly

Endo Pharmaceuticals

Fresenius

Gilead Sciences

GlaxoSmithKline

Grifols

Johnson & Johnson

Kyowa Hakko Kirin

Lundbeck

Merck & Co

Merck KGaA

Mitsubishi Tanabe

Novartis

Novo Nordisk

Otsuka

Pfizer

Roche

Sanofi

Servier

Shionogi

Shire

Takeda

Teva

UCB

Chapter 5 – Big Biotech antibody deals 

5.1. Introduction

5.2. How to use big biotech partnering deals

5.3. Big biotech antibody partnering company profiles

Alexion Pharmaceuticals

Cangene

Elan

Emergent BioSolutions

Galapagos

Genmab

LFB Group

Morphosys

PDL BioPharma

Regeneron Pharmaceuticals

Seattle Genetics

Spectrum Pharmaceuticals

Swedish Orphan Biovitrum

Chapter 6 – Antibody dealmaking directory with contract documents 

6.1. Introduction

6.2. By Company A-Z

Abbott Laboratories

Abbvie

Adimab

ADMA Biologics

Agensys

Alder Biopharmaceuticals

Alexion Pharmaceuticals

Althea Technologies

Amgen

Arana Therapeutics

AstraZeneca

Avecia Biologics

AVEO Pharmaceuticals

Bayer

Bayer Schering Pharma

Biogen Idec

Biotest

Biotest Pharmaceuticals

BioWa

Boehringer Ingelheim

Bristol-Myers Squibb

Cell Therapeutics

Centocor Ortho Biotech

Corgenix Medical

Crucell

Cytodyn

Elan

Eli Lilly

Facet Biotechnology

Fujifilm Diosynth Biotechnologies

GE Healthcare

Genentech

Genzyme

Gilead Sciences

GlaxoSmithKline

GlycArt

Green Cross

ImmunoCellular Therapeutics

ImmunoGen

Intellect Neurosciences

Intrexon

Janssen Pharmaceutica NV

Johnson & Johnson

Kaketsuken

KaloBios Pharmaceuticals

Kyowa Hakko Kirin

Lexicon Pharmaceuticals

Lonza

Lpath

Mabtech

Macrogenics

Massachusetts Biologic Laboratories

Matsuura

Medarex

Merck and Co

Merrimack Pharmaceuticals

MicroCoat Biotechnologie

Micromet

Millennium

MorphoSys

Neotope

Novartis

Novo Nordisk

Orbimed Advisors

Organon

Ortho-McNeil

Oxford Immunotec

PDL BioPharma

Peregrine Pharmaceuticals

Pfizer

PharmAthene

Progenics Pharmaceuticals

Receptos

Regeneron Pharmaceuticals

Repligen

RIT Oncology

Roche

Sanofi-Aventis

Sanofi-Pasteur

Scripps Research Institute

Seattle Genetics

Servier

Sicor Italy

Sorrento Therapeutics

Spectrum Pharmaceuticals

Stason Pharmaceuticals

Synthetic Biologics

Takeda Pharmaceutical

Targepeutics

TrovaGene

TTFactor

UCB

Ultragenyx Pharmaceuticals

University of Texas

Wyeth

Xencor

Xoma

ZymoGenetics

6.3. By stage of development

Discovery

Preclinical

Phase I

Phase II

Phase III

Marketed

6.4. By deal type

Asset purchase

Assignment

Bigpharma outlicensing

Co-development

Collaborative R&D

Contract service

Co-promotion

Cross-licensing

Development

Equity purchase

Evaluation

Licensing

Manufacturing

Marketing

Option

Promotion

Research

Settlement

Supply

Termination

6.5. By therapy area

Cardiovascular

Central Nervous System

Dermatology

Gastrointestinal

Gynaecology

Hematology

Immunology

Infectives

Metabolic

Musculoskeletal

Oncology

Ophthalmics

Orphan disease

Psychiatry

Respiratory

Chapter 7- By antibody technology type 

7.1. Introduction

7.2. Deals by antibody type

Antibodies

  • Antibody-drug conjugates
  • Monoclonal antibodies
    • Murine mAb
    • Chimeric mAb
    • Humanized mAb
    • Human aAb
     
  • Polyclonal Antibodies

Chapter 8 – Antibody partnering resource center 

8.1. Online antibody partnering

8.2. Antibody partnering events

8.3. Further reading on antibody dealmaking

About Wildwood Ventures

Current Partnering

Current Agreements

Recent report titles from CurrentPartnering

Order Form – Reports

Appendices 

Appendix 1- Deals by Company A-Z

Appendix 2- Deals by stage of development

Appendix 3- Deals by deal type

Appendix 4- Deals by therapy area

Appendix 5- Deals by deal type definitions

 

Table of figures 

 Figure 1: Therapeutic antibody definitions

Figure 2: Antibody partnering since 2009

Figure 3: Big pharma – top 50 – antibody deals 2009 to 2014

Figure 4: Big pharma antibody deal frequency – 2009 to 2014

Figure 5: Big biotech antibody deal frequency – 2009 to 2014

Figure 6: Top 10 antibody dealmakers – 2009 to 2014

Figure 7: Antibody partnering by deal type since 2009

Figure 8: Antibody partnering by disease type since 2009

Figure 9: Antibody partnering by oncology target since 2009

Figure 10: Antibody partnering by stage of development since 2009

Figure 11: Antibody partnering by therapeutic antibody type since 2009

Figure 12: Antibody deals with a headline value

Figure 13: Antibody deal headline value distribution, US$million – discovery stage

Figure 14: Antibody deal headline value distribution, US$million – preclinical stage

Figure 15: Antibody deal headline value distribution, US$million – phase I stage

Figure 16: Antibody deal headline value distribution, US$million – phase II stage

Figure 17: Antibody deal headline value distribution, US$million – phase III stage

Figure 18: Antibody deal headline value distribution, US$million – regulatory stage

Figure 19: Antibody deal headline value distribution, US$million – marketed stage

Figure 20: Summary median headline value by stage of development, 2009-2014

Figure 21: Antibody deals with upfront payment values

Figure 22: Antibody deal upfront payment distribution, US$million – discovery stage

Figure 23: Antibody deal upfront payment distribution, US$million – preclinical stage

Figure 24: Antibody deal upfront payment distribution, US$million – phase I stage

Figure 25: Antibody deal upfront payment distribution, US$million – phase II stage

Figure 26: Antibody deal upfront payment distribution, US$million – phase III stage

Figure 27: Antibody deal upfront payment distribution, US$million – regulatory stage

Figure 28: Antibody deal upfront payment distribution, US$million – marketed stage

Figure 29: Summary median upfront payments by stage of development, 2009-2014

Figure 30: Antibody deals with milestone payments

Figure 31: Antibody deal milestone distribution, US$million – discovery stage

Figure 32: Antibody deal milestone distribution, US$million – preclinical stage

Figure 33: Antibody deal milestone distribution, US$million – phase I stage

Figure 34: Antibody deal milestone distribution, US$million – phase II stage

Figure 35: Antibody deal milestone distribution, US$million – phase III stage

Figure 36: Antibody deal milestone distribution, US$million – regulatory stage

Figure 37: Antibody deal milestone distribution, US$million – marketed stage

Figure 38: Antibody deals with royalty rates, %

Figure 39: Antibody deal royalty rate distribution, US$million – discovery stage

Figure 40: Antibody deal royalty rate distribution, US$million – preclinical stage

Figure 41: Antibody deal royalty rate distribution, US$million – phase I stage

Figure 42: Antibody deal royalty rate distribution, US$million – phase II stage

Figure 43: Antibody deal royalty rate distribution, US$million – phase III stage

Figure 44: Antibody deal royalty rate distribution, US$million – regulatory stage

Figure 45: Antibody deal royalty rate distribution, US$million – marketed stage

Figure 46: Summary median royalty rate by stage of development, 2009-2014

Figure 47: Components of the typical antibody deal structure

Figure 48: Top antibody deals by value since 2009

Figure 49: Online partnering resources

Figure 50: Forthcoming partnering events